TBI remains a major cause of death and long-term neurological disability worldwide, yet effective treatments for secondary ...

The bile acid and popular supplement, TUDCA, has the potential to reduce atherosclerosis — the buildup of fatty plaques in ...

Chronic inflammation is a long-lasting reaction of the body’s immune system. While inflammation is normally helpful and ...

A novel oral molecule significantly reduced inflammatory markers linked to development of arteriosclerotic cardiovascular ...

As people get older, many begin to worry about diseases such as Alzheimer’s, diabetes, and cancer. One common factor behind ...

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible ...

In new research, scientists at the Department of Energy's SLAC National Accelerator Laboratory, in collaboration with ...

Inflammasome Therapeutics is teaming up with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital to conduct a clinical trial evaluating its oral therapy candidate kamuvudine-9, ...

NEWTON, Mass.--(BUSINESS WIRE)--#NRTIs--Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and ...

cInstitute of Medical Microbiology, Jena University Hospital, 07747, Jena, Germany dDepartment of Anesthesiology and Intensive Medicine, Jena University Hospital, 07747, Jena, Germany eSeer Bio GmbH - ...

Neushen Therapeutics Inc. has patented NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral ...

Acetaminophen-induced liver injury remains a significant global public health concern due to its potential to cause acute liver failure and mortality in severe cases. The hepatotoxic effects of APAP ...